| 000 | 01724 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517212244.0 | ||
| 264 | 0 | _c20190722 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a2326-5205 | ||
| 024 | 7 |
_a10.1002/art.40511 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDoria, A | |
| 245 | 0 | 0 |
_aEfficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. _h[electronic resource] |
| 260 |
_bArthritis & rheumatology (Hoboken, N.J.) _c08 2018 |
||
| 300 |
_a1256-1264 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Antinuclear _xblood |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aComplement C3 _xdeficiency |
| 650 | 0 | 4 |
_aDNA _ximmunology |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aIntention to Treat Analysis |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aStohl, W | |
| 700 | 1 | _aSchwarting, A | |
| 700 | 1 | _aOkada, M | |
| 700 | 1 | _aScheinberg, M | |
| 700 | 1 | _avan Vollenhoven, R | |
| 700 | 1 | _aHammer, A E | |
| 700 | 1 | _aGroark, J | |
| 700 | 1 | _aBass, D | |
| 700 | 1 | _aFox, N L | |
| 700 | 1 | _aRoth, D | |
| 700 | 1 | _aGordon, D | |
| 773 | 0 |
_tArthritis & rheumatology (Hoboken, N.J.) _gvol. 70 _gno. 8 _gp. 1256-1264 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/art.40511 _zAvailable from publisher's website |
| 999 |
_c28302962 _d28302962 |
||